Arbutus Biopharma Corp

ABUS

$5.13

+0.10%+$0.01

High—

Low—

52W High-6.0%

Rel. vol—

Interval

Range7m

Volume—SMA5SMA10

—

AI analysis

Arbutus Biopharma Corp is showing mixed intraday momentum with consolidation near key moving averages and heightened sensitivity to liquidity shifts.

Upside confirmation strengthens on sustained reclaim above short-term trend anchors.
Breakdown risk rises if support fails with accelerating sell volume.
Relative strength versus sector peers remains neutral-to-slightly positive.

Latest indicator snapshot

Live technical and fundamental context, tuned for quick reads.

SMA5

—

5-period simple moving average

SMA10

—

10-period simple moving average

SMA20

—

20-period simple moving average

SMA50

—

50-period simple moving average

EMA5

$5.12

5-period exponential moving average

EMA10

$5.12

10-period exponential moving average

EMA20

$5.13

20-period exponential moving average

DEMA20

$5.12

Double exponential moving average

Fibonacci

Retracement

Retracement levels

VWAP

$5.13

Volume weighted average price

MACD

-0.002

Signal -0.001

RSI(14)

—

Relative strength oscillator

OBV

-38.91K

On-balance volume

StochRSI

—

Fast oscillator pair

BBands Low

—

Lower band

BBands Mid

—

Middle band

BBands High

—

Upper band

Market Cap

1.01B

Company size

P/E Ratio

6.46

Valuation multiple

EV / EBITDA

5.99

Enterprise value multiple

ROE

89.6%

Return on equity

ROA

48.8%

Return on assets

Operating Margin

-567.0%

Operating efficiency

Net Margin

84.2%

Bottom-line profitability

Current Ratio

—

Short-term liquidity

Debt / Equity

—

Balance-sheet leverage

Dividend Yield

0.0%

Income yield

FCF Yield

—

Free cash flow yield

Beta

0.60

Market sensitivity

52W High

$5.45

52-week peak

52W Low

$3.50

52-week trough

Supply Chain of ABUS

Upstream / Downstream / Proxies

Upstream

Genevant Sciences Ltd.Third-Party CDMOs (Drug Substance & Drug Product Manufacturing)X-Chem Inc.Proteros biostructures GmbHLipid Excipient Manufacturers (CordenPharma, Merck KGaA, etc.)Oligonucleotide Raw Material Suppliers

Downstream

Moderna, Inc.NASDAQ:MRNA Alnylam Pharmaceuticals, Inc.NASDAQ:ALNY Barinthus Biotherapeutics plcNASDAQ:BRNS Roivant Sciences Ltd.NASDAQ:ROIVAcuitas Therapeutics Inc.Qilu Pharmaceutical Co., Ltd.Gritstone bio, Inc. (fka Gritstone Oncology)

Proxies

Alnylam Pharmaceuticals, Inc.NASDAQ:ALNY Moderna, Inc.NASDAQ:MRNA Roivant Sciences Ltd.NASDAQ:ROIV Barinthus Biotherapeutics plcNASDAQ:BRNS Gilead Sciences, Inc.NASDAQ:GILD

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer